Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

Fibroblast growth factors (FGFs) 15/19 and 21 belong to a subfamily of FGFs that function as hormones. Produced in response to specific nutritional cues, they act on overlapping sets of cell surface receptors composed of classic FGF receptors in complex with βKlotho, and regulate metabolism and related processes during periods of fluctuating energy availability. Pharmacologically, both FGF15/19 and FGF21 cause weight loss and improve both insulin-sensitivity and lipid parameters in rodent and primate models of metabolic disease. Recently, FGF21 was shown to have similar effects in obese patients with type 2 diabetes. We discuss here emerging concepts in FGF15/19 and FGF21 tissue-specific actions and critically assess their putative role as candidate targets for treating metabolic disease.

Original languageEnglish (US)
Pages (from-to)22-29
Number of pages8
JournalTrends in Endocrinology and Metabolism
Volume26
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Hormones
Metabolic Diseases
Fibroblast Growth Factor Receptors
Fibroblast Growth Factors
Cell Surface Receptors
Type 2 Diabetes Mellitus
Primates
Cues
Insulin Resistance
Weight Loss
Rodentia
Lipids
fibroblast growth factor 21

Keywords

  • Arginine vasopressin
  • Brown adipose tissue
  • Corticotropin-releasing factor
  • Hypothalamus
  • Sympathetic nervous system
  • βKlotho

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. / Owen, Bryn M.; Mangelsdorf, David J.; Kliewer, Steven A.

In: Trends in Endocrinology and Metabolism, Vol. 26, No. 1, 01.01.2015, p. 22-29.

Research output: Contribution to journalArticle

@article{809425dce4404ba8a5209c7c0296c5e9,
title = "Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21",
abstract = "Fibroblast growth factors (FGFs) 15/19 and 21 belong to a subfamily of FGFs that function as hormones. Produced in response to specific nutritional cues, they act on overlapping sets of cell surface receptors composed of classic FGF receptors in complex with βKlotho, and regulate metabolism and related processes during periods of fluctuating energy availability. Pharmacologically, both FGF15/19 and FGF21 cause weight loss and improve both insulin-sensitivity and lipid parameters in rodent and primate models of metabolic disease. Recently, FGF21 was shown to have similar effects in obese patients with type 2 diabetes. We discuss here emerging concepts in FGF15/19 and FGF21 tissue-specific actions and critically assess their putative role as candidate targets for treating metabolic disease.",
keywords = "Arginine vasopressin, Brown adipose tissue, Corticotropin-releasing factor, Hypothalamus, Sympathetic nervous system, βKlotho",
author = "Owen, {Bryn M.} and Mangelsdorf, {David J.} and Kliewer, {Steven A.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.tem.2014.10.002",
language = "English (US)",
volume = "26",
pages = "22--29",
journal = "Trends in Endocrinology and Metabolism",
issn = "1043-2760",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21

AU - Owen, Bryn M.

AU - Mangelsdorf, David J.

AU - Kliewer, Steven A.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Fibroblast growth factors (FGFs) 15/19 and 21 belong to a subfamily of FGFs that function as hormones. Produced in response to specific nutritional cues, they act on overlapping sets of cell surface receptors composed of classic FGF receptors in complex with βKlotho, and regulate metabolism and related processes during periods of fluctuating energy availability. Pharmacologically, both FGF15/19 and FGF21 cause weight loss and improve both insulin-sensitivity and lipid parameters in rodent and primate models of metabolic disease. Recently, FGF21 was shown to have similar effects in obese patients with type 2 diabetes. We discuss here emerging concepts in FGF15/19 and FGF21 tissue-specific actions and critically assess their putative role as candidate targets for treating metabolic disease.

AB - Fibroblast growth factors (FGFs) 15/19 and 21 belong to a subfamily of FGFs that function as hormones. Produced in response to specific nutritional cues, they act on overlapping sets of cell surface receptors composed of classic FGF receptors in complex with βKlotho, and regulate metabolism and related processes during periods of fluctuating energy availability. Pharmacologically, both FGF15/19 and FGF21 cause weight loss and improve both insulin-sensitivity and lipid parameters in rodent and primate models of metabolic disease. Recently, FGF21 was shown to have similar effects in obese patients with type 2 diabetes. We discuss here emerging concepts in FGF15/19 and FGF21 tissue-specific actions and critically assess their putative role as candidate targets for treating metabolic disease.

KW - Arginine vasopressin

KW - Brown adipose tissue

KW - Corticotropin-releasing factor

KW - Hypothalamus

KW - Sympathetic nervous system

KW - βKlotho

UR - http://www.scopus.com/inward/record.url?scp=84920483737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920483737&partnerID=8YFLogxK

U2 - 10.1016/j.tem.2014.10.002

DO - 10.1016/j.tem.2014.10.002

M3 - Article

VL - 26

SP - 22

EP - 29

JO - Trends in Endocrinology and Metabolism

JF - Trends in Endocrinology and Metabolism

SN - 1043-2760

IS - 1

ER -